• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'.

作者信息

Martora Fabrizio, Marasca Claudio, Fabbrocini Gabriella, Ruggiero Angelo

机构信息

Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

出版信息

Clin Exp Dermatol. 2022 Oct;47(10):1864-1865. doi: 10.1111/ced.15291. Epub 2022 Jul 12.

DOI:10.1111/ced.15291
PMID:35699658
Abstract
摘要

相似文献

1
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'.意大利南部一家转诊中心为减少阿达木单抗停药所采取的策略：对“我们能否延长化脓性汗腺炎生物治疗的药物存活时间？”的评论
Clin Exp Dermatol. 2022 Oct;47(10):1864-1865. doi: 10.1111/ced.15291. Epub 2022 Jul 12.
2
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
3
Update on Hidradenitis Suppurative (Part II): Treatment.化脓性汗腺炎（第二部分）：治疗进展
Actas Dermosifiliogr. 2015 Nov;106(9):716-24. doi: 10.1016/j.ad.2015.06.005. Epub 2015 Aug 12.
4
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.高剂量、高频度乌司奴单抗治疗重度化脓性汗腺炎患者。
Br J Dermatol. 2022 Sep;187(3):417-419. doi: 10.1111/bjd.21066. Epub 2022 May 18.
5
Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases.18岁以下化脓性汗腺炎患者使用肿瘤坏死因子抑制剂的治疗：12例病例系列
J Am Acad Dermatol. 2020 Jul;83(1):199-201. doi: 10.1016/j.jaad.2020.02.071. Epub 2020 Mar 6.
6
Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.中度至重度化脓性汗腺炎生物治疗的概述与更新
Semin Cutan Med Surg. 2018 Sep;37(3):182-189. doi: 10.12788/j.sder.2018.042.
7
Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.分析南方美国队列研究中化脓性汗腺炎患者治疗反应的特征和趋势。
Dermatology. 2020;236(5):413-420. doi: 10.1159/000504843. Epub 2020 Jan 14.
8
Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.目前用于治疗化脓性汗腺炎的生物疗法的代谢、药代动力学和毒理学问题。
Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1019-1037. doi: 10.1080/17425255.2020.1810233. Epub 2020 Oct 12.
9
Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: A cross-sectional analysis.化脓性汗腺炎中肿瘤坏死因子α抑制剂的低处方率：一项横断面分析。
J Am Acad Dermatol. 2021 May;84(5):1399-1401. doi: 10.1016/j.jaad.2020.07.108. Epub 2020 Aug 3.
10
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.阿达木单抗和英夫利昔单抗治疗化脓性汗腺炎患者的生存情况：一项日常实践队列研究。
Br J Dermatol. 2021 Jul;185(1):177-184. doi: 10.1111/bjd.19863. Epub 2021 May 4.

引用本文的文献

1
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes-A Review of the Literature.老年化脓性汗腺炎患者：临床和治疗结果——文献综述。
Medicina (Kaunas). 2024 Sep 6;60(9):1465. doi: 10.3390/medicina60091465.
2
Hidradenitis suppurativa: a new therapeutic approach for an old disease.化脓性汗腺炎：一种针对古老疾病的新治疗方法。
Postepy Dermatol Alergol. 2024 Aug;41(4):350-356. doi: 10.5114/ada.2024.142185. Epub 2024 Aug 12.
3
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report.
古塞库单抗治疗青少年化脓性汗腺炎的长期疗效：一例报告
Clin Cosmet Investig Dermatol. 2024 Feb 29;17:483-487. doi: 10.2147/CCID.S456817. eCollection 2024.
4
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.司库奇尤单抗用于阿达木单抗治疗失败的化脓性汗腺炎患者：一项52周的真实世界研究。
Clin Cosmet Investig Dermatol. 2024 Jan 23;17:159-166. doi: 10.2147/CCID.S449367. eCollection 2024.
5
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review.新型冠状病毒肺炎疫苗接种后玫瑰糠疹及玫瑰糠疹样皮疹：一项叙述性综述
Clin Cosmet Investig Dermatol. 2024 Jan 8;17:51-57. doi: 10.2147/CCID.S447834. eCollection 2024.
6
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.儿童中重度斑块状银屑病的管理策略：聚焦生物制剂
Pediatric Health Med Ther. 2023 Nov 14;14:435-451. doi: 10.2147/PHMT.S389108. eCollection 2023.
7
JAK Inhibitors in Psoriatic Disease.银屑病疾病中的JAK抑制剂
Clin Cosmet Investig Dermatol. 2023 Oct 31;16:3129-3145. doi: 10.2147/CCID.S433367. eCollection 2023.
8
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
9
Dermatologists' Perceptions of the Use of Teledermatology in Managing Hidradenitis Suppurativa: Survey Study.皮肤科医生对使用远程皮肤病学管理化脓性汗腺炎的看法：调查研究
JMIR Dermatol. 2023 Jan 31;6:e43910. doi: 10.2196/43910.
10
Self-Perceived Social Support of Patients with Chronic Skin Diseases in Saudi Arabia: A Cross-Sectional Survey.沙特阿拉伯慢性皮肤病患者的自我感知社会支持：一项横断面调查。
J Clin Med. 2023 Aug 20;12(16):5406. doi: 10.3390/jcm12165406.